Hydrocortisone sodium succinate
Chemical compound
- US DailyMed: Hydrocortisone sodium succinate
administration
- A01AC03 (WHO)
- Sodium 4-[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoate
- 125-04-2
- 23694214
- DBSALT001297
- 390144
- 50LQB69S1Z
- D00978
- CHEBI:5782
- ChEMBL1200495
- DTXSID2049006
- Interactive image
- C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COC(=O)CCC(=O)[O-])O)C)O.[Na+]
- InChI=1S/C25H34O8.Na/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30;/h11,16-18,22,27,32H,3-10,12-13H2,1-2H3,(H,29,30);/q;+1/p-1/t16-,17-,18-,22+,23-,24-,25-;/m0./s1
- Key:HHZQLQREDATOBM-CODXZCKSSA-M
Hydrocortisone sodium succinate, sold under the brand name Solu-Cortef among others, is a synthetic glucocorticoid corticosteroid and a corticosteroid ester.[3]
Hydrocortisone sodium succinate was approved for medical use in the United States in 1955.[2]
References
- ^ "CIPLA HYDROCORTISONE, CORTI-H, CORTICIP, HYDROCIP (Cipla Australia Pty Ltd)". Department of Health and Aged Care. Archived from the original on 18 March 2023.
- ^ a b "Solu-Cortef- hydrocortisone sodium succinate injection, powder, for solution". DailyMed. 19 August 2021. Retrieved 23 December 2023.
- ^ Brownell CL, Priff N (2009). "Hydrocortisone". Nursing2009 Student Drug Handbook (10th ed.). Philadelphia: Wolters Kluwer. p. 642. ISBN 978-0-7817-8883-0.
- v
- t
- e
- Antagonists: Aglepristone
- Ketoconazole
- Mifepristone
- Ulipristal acetate
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Glucocorticoid receptor modulators
- Mineralocorticoids and antimineralocorticoids
- List of corticosteroids
Portal:
Medicine
 | This article about a steroid is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
